HORIZON-PFT: Pivotal Fracture Trial
HORIZON-PFT: Pivotal Fracture Trial
HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per
 year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures
 are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine
 the benefits of zoledronic acid in fracture reduction at both the hip and spine.
Inclusion Criteria:

 -  Female, 65-89 years old

 -  No history of severe liver, kidney or eye disease

 Exclusion Criteria:

 -  Current bisphosphonate users such as Aredia® (pamidronate), Didronel® (etidronate),
 Fosamax® (alendronate), Actonel® (risedronate), Skelid® (tiludronate)

 -  Using hip protectors

 Other protocol-defined inclusion/exclusion criteria may apply.